Diketopiperazine salts for drug delivery and related methods
Drug delivery systems have been developed based on the formation of diketopiperazine carboxylate salts and microparticles containing the same. The systems may further comprise a bioactive agent. Related methods for making and using the biologically active agent delivery compositions are also provided. In certain embodiments, the pharmaceutically acceptable salts described can be formed by removal of solvent by methods including distillation, evaporation, spray drying or lyophilization.
1. A method of preparing a solid composition for drug delivery comprising:
preparing a solution containing a biologically active agent and a pharmaceutically-acceptable salt of a heterocyclic compound in a solvent;
and a step for removing said solvent;
wherein said pharmaceutically acceptable salt of a heterocyclic compound has the structure according to Formula 1:
wherein R 1 and R 2 are independently selected from 4-succinyl-aminobutyl, 4-glutaryl-aminobutyl, 4-maleyl-aminobutyl, 4-fumaryl-aminobutyl, 4-citraconyl-aminobutyl, 4-malonyl-aminobutyl, 4-oxalyl-aminobutyl;
E 1 and E 2 are NH; and
said salt further comprises at least one cation.
2. The method of claim 1 , wherein said step for removing said solvent comprises distillation.
3. The method of claim 1 , wherein said step for removing said solvent comprises evaporation.
4. The method of claim 1 , wherein said step for removing said solvent comprises spray drying.
5. The method of claim 1 , wherein said step for removing said solvent comprises lyophilization.
6. The method of claim 1 , wherein said at least one cation is selected from the group consisting of sodium, potassium, calcium, magnesium, lithium, triethylamine, butylamine, diethanolamine, and triethanolamine.
7. The method of claim 1 , wherein said at least one cation is sodium.
8. The method of claim 1 , wherein said biologically active agent is selected from the group consisting of hormones, anticoagulants, immunomodulating agents, cytotoxic agents, antibiotics, antivirals, antisense, anti-inflammatories, vasoactive agents, neuroactive agents, cannabinoids, antigens, antibodies and active fragments and analogues thereof.
9. The method of claim 1 further comprising the step of micronizing said solid to form a dry powder.
10. The method of claim 9 , wherein the particles of said dry powder are suitable for pulmonary delivery.
11. The method of claim 9 , wherein the particles of said dry powder have a rugosity of less than 2.
12. The method of claim 1 , wherein said solid composition comprises microparticles.
13. The method of claim 12 , wherein at least 50% of said particles have a diameter less than 5 μm.
14. The method of claim 12 , wherein at least 70% of said particles have a diameter less than 5 μm.
15. The method of claim 12 , wherein said microparticles have a rugosity of less than 2.
16. The method of claim 12 , wherein said microparticles comprise a dry powder.
17. The method of claim 12 , wherein said microparticles are suitable for pulmonary delivery.
18. The method of claim 1 , wherein said solid composition is a precipitate.
19. The method of claim 1 , wherein said solid composition is formulated into a solid dosage form.